NCT02937675 is a Phase 1, PHASE2 clinical trial of Tomivosertib (eFT-508) in Lymphoma, sponsored by Effector Therapeutics.

Who is sponsoring NCT02937675?

NCT02937675 is sponsored by Effector Therapeutics.

What drugs are being tested in NCT02937675?

Interventions in NCT02937675: Tomivosertib (eFT-508).

Is NCT02937675 still recruiting?

NCT02937675 is currently terminated. Last updated 2 November 2020.

Last reviewed 2020-11-02 · How we verify

NCT02937675

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Terminated Phase 1, PHASE2 Last updated 2 November 2020

What this trial tests

Phase 1, PHASE2 trial testing Tomivosertib (eFT-508) in Lymphoma in 28 participants. Terminated before completion.

Timeline

8 February 2017

Primary endpoint
12 November 2018

4 April 2019

Quick facts

Lead sponsor	Effector Therapeutics
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	8 February 2017
Primary completion	12 November 2018
Estimated completion	4 April 2019
Sites	10 locations across United States

Drugs / interventions tested

Tomivosertib (eFT-508) — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Effector Therapeutics — full company profile →

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508). The study will evaluate oral daily administration of Tomivosertib (eFT-508). Treatment and study subject evaluation will be performed in 21-day cycles.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Xu Y, Poggio M, Jin HY, Shi Z, et al · · 2019 · cited 227× · PMID 30643286 · DOI 10.1038/s41591-018-0321-2
The regulation of protein translation and its implications for cancer.
Song P, Yang F, Jin H, Wang X. · · 2021 · cited 106× · PMID 33597534 · DOI 10.1038/s41392-020-00444-9
Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer.
Pinto-Díez C, Ferreras-Martín R, Carrión-Marchante R, González VM, et al · · 2020 · cited 41× · PMID 32340135 · DOI 10.3390/ijms21082967
Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.
Taylor J, Yeomans AM, Packham G. · · 2020 · cited 10× · PMID 32924027 · DOI 10.37349/etat.2020.00002
Targeting protein synthesis pathways in MYC-amplified medulloblastoma.
Kumar D, Kanchan R, Chaturvedi NK. · · 2025 · cited 5× · PMID 39779613 · DOI 10.1007/s12672-025-01761-7
RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications.
Huang S, Li Z, Lin W, Xie R, et al · · 2025 · cited 3× · PMID 40761481 · DOI 10.1002/mco2.70322
MNK Proteins as Therapeutic Targets in Leukemia.
Mazewski C, Platanias LC. · · 2023 · cited 3× · PMID 37113687 · DOI 10.2147/ott.s370874

Verify or expand the search:

Other trials of Tomivosertib (eFT-508)

Trials testing the same drug.

NCT03616834 — Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy · Phase 2 · completed

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Effector Therapeutics trials

Trials by the same sponsor.

NCT04632381 — Intravenous Zotatifin in Adults With Mild or Moderate COVID-19 · Phase 1 · completed
NCT04622007 — Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) · Phase 2 · active not recruiting
NCT04092673 — Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies · Phase 1, PHASE2 · recruiting
NCT03690141 — An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer · Phase 2 · terminated
NCT03616834 — Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02937675 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Effector Therapeutics
Last refreshed: 2 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02937675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing